Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in Adults With Hypereosinophilic Syndrome (HES)
NCT05334368Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2022
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of depemokimab in hypereosinophilic syndrome (HES), sponsored by GSK. Started Sep 2022; status: active, not recruiting.
02
Drugs
depemokimab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT05334368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05334368.